Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Hepatic steatosis secondary to capecitabine: a case report. | Chin et al. Journal of Medical Case Reports 2010 4 227 http content 4 1 227 jAg JOURNALOF medical ÌỤr case REPORTS CASE REPORT Open Access Hepatic steatosis secondary to capecitabine a case report Sheray N Chin1 Tae K Kim2 Lillian L Siu1 Abstract Introduction There are no known case reports of hepatic steatosis caused by oral fluoropyrimidines such as capecitabine. With increasing use of capecitabine since its approval for the treatment of metastatic colon cancer in 2001 and more recently for adjuvant treatment of colon cancer and treatment of metastatic breast cancer we can anticipate increased recognition of potential toxicities associated with this 5-fluorouracil derivative. Case presentation We report the case of a 74-year-old Armenian woman who received capecitabine as adjuvant treatment for colon cancer and subsequently developed abnormal liver biochemical tests and radiographic findings in keeping with hepatic steatosis. There was complete reversal of liver enzyme abnormalities with discontinuation of the drug and this patient represents a case of reversible liver injury due to capecitabine. Conclusion In this original case report capecitabine use was associated with hepatic steatosis. It is important for clinicians to recognize and monitor for this potential toxicity which may be a cause of abnormal liver enzymes in this patient population. Introduction Capecitabine is an orally administered precursor of 5-fluorouracil 5-FU a fluoropyrimidine antimetabolite. It is converted to 5-FU preferentially in tumor tissue and also in the liver by way of a three-step enzymatic cascade 1 . Capecitabine is a relatively new agent with FDA approval in 2001 for use as an alternative to the Mayo Clinic 5-FU folinic acid regimen for metastatic colon cancer. It has since been approved for use in the adjuvant treatment of colon cancer as well as for metastatic breast cancer. Hepatic steatosis a mild manifestation of nonalcoholic fatty liver disease
